Peptide LibraryPetrelintide
Also known as: ZP8396, Long-acting amylin analog
Petrelintide (also called ZP8396 or Long-acting amylin analog) is an investigational amylin analog. Petrelintide is a long-acting amylin receptor agonist in clinical development, engineered for stability and once-weekly administration. It engages amylin and calcitonin receptor complexes in hindbrain nuclei, principally the area postrema, where amylin signalling slows gastric emptying and reduces meal size.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- About 10 days (phase 1 trials)
- FDA status
- Investigational New Drug (IND)
- Evidence level
- Clinical Trial Evidence
- Human dose established
- Yes
- Administration Route
- Subcutaneous
- Frequency
- Once weekly
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Amylin receptor
Research summary
Investigational long-acting amylin receptor agonist from Zealand Pharma, engineered for once-weekly dosing and in clinical development for obesity. Amylin agonists reduce food intake through hindbrain pathways separate from incretin signalling, so they are being studied both alone and alongside GLP-1 receptor agonists. Not FDA-approved.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trials3 reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Petrelintide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Petrelintide dosage evidence
Petrelintide has no approved dosage. Human dosing comes from Zealand Pharma's trials of once-weekly injections under the skin: in the ZUPREME 1 phase 2 trial, maintenance doses of 1.0 to 9.0 mg lowered body weight by 7.9% to 9.8% after 28 weeks against 1.7% with placebo in adults with obesity. Phase 3 trials are recruiting.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 1.0–9.0 mg once weekly in the phase 2 trial |
| Route | Subcutaneous |
| Frequency | Once weekly |
| Duration studied | 16 weeks in phase 1; 28 weeks (with follow-up to week 42) in phase 2 |
| Titration | The phase 1 multiple-dose trial escalated every 2 weeks to target doses; ZUPREME 1 reports nausea mainly during dose escalation, but its step schedule is not given in the indexed abstract. |
| Half-life | About 10 days (phase 1 trials) |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| ZUPREME 1 — phase 2, obesity (NCT06662539)Clinical trial · Randomized, double-blind, placebo-controlled phase 2 trial | Adults with obesity, or BMI ≥27 with hypertension or dyslipidaemia, without type 2 diabetes (485 dosed) | Maintenance doses of 1.0, 2.5, 5.0, 7.0 or 9.0 mg | Subcutaneous | Once weekly | 28 weeks (primary endpoint); follow-up to week 42 | Mean weight change from -7.9% to -9.8% across doses against -1.7% with placebo; nausea in 20% against 6% | Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2026. |
| Phase 1 single and multiple ascending dosesClinical trial · Two randomized, double-blind, placebo-controlled phase 1 trials | Adults of normal weight or overweight (single dose and MAD part 1); adults with overweight or obesity (MAD part 2) | Single doses of 0.04–2.4 mg (and 0.35 mg intravenously); 0.6 or 1.2 mg weekly for 6 doses; 16 weekly doses escalated to 2.4, 4.8 or 9.0 mg | Subcutaneous | Single dose or once weekly | Up to 16 weeks | Well tolerated with no serious or severe adverse events; weight down by up to 8.6% after 16 weeks | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. Diabetes Obes Metab. 2026. |
| Phase 3, obesity with cardiovascular disease (NCT07843472)Clinical trial · Phase 3 randomized, placebo-controlled trial | Adults with overweight or obesity and established cardiovascular disease (n=2,500 planned) | Per trial protocol (dose not given in the registry) | Subcutaneous | Per trial protocol | 64 weeks (primary endpoint) | Recruiting; no results | NCT07843472 — A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease |
Where sources disagree
- Petrelintide is an amylin analogue, like cagrilintide, but it is a different molecule with its own trial doses; cagrilintide doses do not transfer to petrelintide.
- Weight loss in ZUPREME 1 was similar from 5.0 to 9.0 mg. Phase 3 doses are not listed in the registry, and petrelintide is not FDA-approved.
Handling & administration
- Timing Notes
- Phase 2b (ZUPREME-1) in obesity
Sequence & molecular data
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| Half-life | Long-acting (once-weekly; precise human t½ not yet widely published) |
| Appearance | Investigational sc formulation |
| Formulation | Lyophilized Powder |
| PubChem CID | 172915807 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Petrelintide is a long-acting amylin receptor agonist in clinical development, engineered for stability and once-weekly administration. It engages amylin and calcitonin receptor complexes in hindbrain nuclei, principally the area postrema, where amylin signalling slows gastric emptying and reduces meal size. The developmental thesis for amylin agonists is that they reduce food intake through a mechanism distinct from incretin signalling, potentially with a different tolerability profile, and can be used alone or alongside a GLP-1 receptor agonist. Efficacy and safety remain under investigation and it is not approved for any use.
Origin
Synthetic long-acting amylin analog.
Targets
Studies
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials
- Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue
- Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
- Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs
Research statistics
8 PubMed publications · 25.0% human clinical research · 12 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Petrelintide has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Clinical Trial |
How FDA approval, compounding and research-only status differ
Benefits
Petrelintide side effects
The effects below are those reported in Petrelintide clinical trials; long-term safety data may still be limited.
Side Effects
- Nausea
- GI effects
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Petrelintide: frequently asked questions
What is Petrelintide?
Investigational long-acting amylin receptor agonist from Zealand Pharma, engineered for once-weekly dosing and in clinical development for obesity. Amylin agonists reduce food intake through hindbrain pathways separate from incretin signalling, so they are being studied both alone and alongside GLP-1 receptor agonists. Not FDA-approved.
How does Petrelintide work?
Petrelintide is a long-acting amylin receptor agonist in clinical development, engineered for stability and once-weekly administration. It engages amylin and calcitonin receptor complexes in hindbrain nuclei, principally the area postrema, where amylin signalling slows gastric emptying and reduces meal size.
Is Petrelintide FDA approved?
No. Petrelintide is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.
What is the half-life of Petrelintide?
Reported half-life for Petrelintide is Long-acting (once-weekly; precise human t½ not yet widely published). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Petrelintide banned in sport?
Petrelintide is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to Petrelintide?
Compounds most often compared with Petrelintide include Cagrilintide, Pramlintide, CagriSema and Amycretin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials — Diabetes Obes Metab, 2026External reference
- Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue — J Med Chem, 2025External reference
- Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies — Vascul Pharmacol, 2026External reference
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes — Peptides, 2026External reference
- Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs — Pharmacol Res, 2026External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Petrelintide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Petrelintide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →